| アイテムタイプ |
学術雑誌掲載論文(1) |
| 公開日 |
2026-03-26 |
| タイトル |
|
|
タイトル |
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 著者 |
Maeda Haruka
Saito Nobuo
Igarashi Ataru
Ishida Masayuki
Terada Mayumi
Masuda Shingo
Osawa Ryosuke
Hosokawa Naoto
Nakashima Kei
Kamura Hiroshi
Imura Haruki
Inoue Hiroki
Matsuzaka Suguru
Sugimoto Yukihiro
Kuwamitsu Osamu
Motohashi Iori
Morikawa Toru
Oda Rentaro
Hoshina Yuiko
Matono Takashi
Teshigahara Osamu
Sando Eiichiro
Asami Sadaharu
Kudo Satoshi
Akizuki Noboru
Muto Yoshikazu
Hayakawa Tomoichiro
Kishaba Tomoo
Ohara Yasuji
Kubo Yoshinao
Suzuki Motoi
Morimoto Konosuke
|
| キーワード |
|
|
言語 |
en |
|
主題 |
BA.5, COVID-19, Japan, SARS-CoV-2, monovalent, vaccine effectiveness |
| 識別子 |
|
|
識別子 |
https://doi.org/10.1080/14760584.2024.2310807 |
|
識別子タイプ |
DOI |
| 書誌情報 |
en : Expert review of vaccines
巻 23,
号 1,
p. 213-225,
ページ数 15,
発行日 2024-02-08
|
| 出版者 |
|
|
出版者 |
Informa UK Limited |
|
言語 |
en |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1744-8395 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 権利情報 |
|
|
権利情報 |
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permitsunrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow theposting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
Effectiveness of primary series first and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections .pdf (5.3 MB)
.png)
